Aura Biosciences (AURA) Gains from Investment Securities (2021 - 2022)

Aura Biosciences (AURA) posted Gains from Investment Securities of -$61000.0 for Q2 2022, down 238.64% on a QoQ basis from $44000.0 in Q1 2022, and down 2133.33% year-over-year from $3000.0 in Q2 2021.

Aura Biosciences (AURA) Gains from Investment Securities (2021 - 2022) Analysis & Trends

Aura Biosciences' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$61000.0 for Q2 2022.

  • Quarterly Gains from Investment Securities fell 2133.33% year-over-year to -$61000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$5000.0 (changed N/A YoY) and the FY2021 annual result came in at $11000.0, up 466.67% from the prior year.
  • Gains from Investment Securities was -$61000.0 for Q2 2022 at Aura Biosciences, down from $44000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $44000.0 in Q1 2022 and bottomed at -$61000.0 in Q2 2022.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn -
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 472.89 Bn 468.10 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.12 Bn 114.87 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.04 Bn 61.29 Bn 3.31 Bn
7 Belite Bio 62.68 Bn 62.68 Bn -
8 Argenx Se 55.90 Bn 50.72 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.47 Bn 34.46 Bn 959.66 Mn
10 Aura Biosciences 485.29 Mn 400.49 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2022 -61,000.00
Jun 30, 2022 -61,000.00
Mar 31, 2022 44,000.00
Mar 31, 2022 44,000.00
Dec 31, 2021 12,000.00
Dec 31, 2021 12,000.00
Jun 30, 2021 3,000.00
Jun 30, 2021 3,000.00
Mar 31, 2021 -4,000.00
Mar 31, 2021 -4,000.00